Activation of the central melanocortin system contributes to the increased arterial pressure in obese Zucker rats.
We have previously demonstrated that leptin-mediated activation of the central nervous system (CNS) melanocortin system reduces appetite and increases sympathetic activity and blood pressure (BP). In the present study we examined whether endogenous melanocortin system activation, independent of leptin's actions, contributes to the regulation of BP and metabolic functions in obese Zucker rats, which have mutated leptin receptors. The long-term cardiovascular and metabolic effects of central melanocortin-3/4 receptor (MC3/4R) antagonism with SHU-9119 were assessed in lean (n = 6) and obese (n = 8) Zucker rats. BP and heart rate (HR) were measured 24-h/day by telemetry and an intracerebroventricular cannula was placed in the brain lateral ventricle. After stable control measurements, SHU-9119 was infused intracerebroventricularlly (1 nmol/h) for 10 days followed by a 10-day recovery period. Chronic CNS MC3/4R antagonism significantly increased food intake and body weight in lean (20 ± 1 to 45 ± 2 g and 373 ± 11 to 432 ± 14 g) and obese (25 ± 2 to 35 ± 2 g and 547 ± 10 to 604 ± 11 g) rats. No significant changes were observed in plasma glucose levels in lean or obese rats, whereas plasma leptin and insulin levels markedly increased in lean Zucker rats during CNS MC3/4R antagonism. Chronic SHU-9119 infusion in obese Zucker rats reduced mean arterial pressure (MAP) and HR by 6 ± 1 mmHg and 24 ± 5 beats/min, whereas in lean rats SHU-9119 infusion reduced HR by 31 ± 9 beats/min while causing only a transient decrease in MAP. These results suggest that in obese Zucker rats the CNS melanocortin system contributes to elevated BP independent of leptin receptor activation.
Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, MS 39216-4505, USA. jdocarmo@umc.edu
Jussara M
JM
do Carmo
Alexandre A
AA
da Silva
John S
JS
Rushing
John E
JE
Hall
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure / Q000502:physiology*; D002490:Central Nervous System / Q000502:physiology*; D004195:Disease Models, Animal; D006339:Heart Rate / Q000502:physiology; D006973:Hypertension / Q000503:physiopathology*; D057967:Infusions, Intraventricular; D007328:Insulin / Q000097:blood; D008297:Male; D053486:Melanocortins / Q000502:physiology*; D009074:Melanocyte-Stimulating Hormones / Q000008:administration & dosage / Q000494:pharmacology; D009765:Obesity / Q000097:blood / Q000503:physiopathology*; D051381:Rats; D011924:Rats, Zucker; D044104:Receptor, Melanocortin, Type 3 / Q000037:antagonists & inhibitors / Q000187:drug effects; D044105:Receptor, Melanocortin, Type 4 / Q000037:antagonists & inhibitors / Q000187:drug effects; D054411:Receptors, Leptin / Q000502:physiology
D001786:Blood Glucose; D007328:Insulin; D053486:Melanocortins; D044104:Receptor, Melanocortin, Type 3; D044105:Receptor, Melanocortin, Type 4; D054411:Receptors, Leptin; C103272:SHU 9119; D009074:Melanocyte-Stimulating Hormones